Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer –

– Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer –

Read more at globenewswire.com